Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic<i>ANK3-RET</i>Fusion in<i>EGFR</i>-Mutated Non–Small-Cell Lung Cancer

Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC

Suresh S. Ramalingam, Johan Vansteenkiste, David Planchard et al. · New England Journal of Medicine · 2019 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +17

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers

Collin M. Blakely, Thomas B.K. Watkins, Wei Wu et al. · Nature Genetics · 2017 · 578 citations

Medicine, Genetics, Oncology +16

High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden

Ryma Benayed, Michael Offin, Kerry Mullaney et al. · Clinical Cancer Research · 2019 · 496 citations · Full text

Life Sciences, Genetics, Oncology +17

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 445 citations

Medicine, Oncology, Pharmacology +17

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

Youjin Kim, Boram Lee, Joonho Shim et al. · Journal of Thoracic Oncology · 2018 · 191 citations · Full text

Medicine, Genetics, Oncology +14